Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Orexigen Therapeutic (OREX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 51,325
  • Shares Outstanding, K 15,230
  • Annual Sales, $ 33,710 K
  • Annual Income, $ -24,520 K
  • 36-Month Beta 2.64
  • Price/Sales 1.63
  • Price/Cash Flow 0.00
  • Price/Book 0.92

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.41 +39.83%
on 04/07/17
4.00 -15.75%
on 03/30/17
-0.87 (-20.52%)
since 03/28/17
3-Month
2.41 +39.83%
on 04/07/17
5.70 -40.88%
on 02/10/17
+0.03 (+0.90%)
since 01/27/17
52-Week
1.65 +104.24%
on 12/14/16
6.50 -48.15%
on 06/08/16
-1.33 (-28.30%)
since 04/28/16

Most Recent Stories

More News
Today's Research Reports on Stocks to Watch: GrubHub and Orexigen Therapeutics

NEW YORK, NY / ACCESSWIRE / April 28, 2017 / Strong corporate earnings outweighed losses by the energy sector Thursday as U.S. crude futures slipped on growing output concerns. The Dow Jones Industrial...

OREX : 3.37 (-6.65%)
GRUB : 42.98 (+0.14%)
Orexigen Therapeutics Announces New Drug Submission for Contrave© in Canada

Orexigen Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company helping to improve the health and lives of patients struggling with weight loss, today announced that Health Canada has completed...

VRX.TO : 12.65 (-0.86%)
OREX : 3.37 (-6.65%)
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Orexigen Therapeutics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors

Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of...

OREX : 3.37 (-6.65%)
Orexigen Releases Q4 Results, Vivus Reacquires Stendra from Sanofi

NEW YORK, NY / ACCESSWIRE / March 30, 2017 / Orexigen has released their 2016 fourth quarter results. The revenues are surprisingly soaring high, but the stocks are currently not doing as well as expected...

OREX : 3.37 (-6.65%)
VVUS : 1.01 (-1.94%)
Orexigen Posts Wider-than-Expected Loss in Q4; Sales Up Y/Y

Orexigen Therapeutics, Inc.???s (OREX) loss of $2.67 per share in the fourth quarter of 2016, significantly wider than the both Zacks Consensus Estimate of a loss of 54 cents and the year-ago loss of $1.20....

HSKA : 108.25 (+2.88%)
OREX : 3.37 (-6.65%)
ALQA : 0.40 (-6.98%)
ADUS : 33.95 (+0.30%)
Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2016

Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced business and financial results for the fourth quarter and year ended December 31, 2016.

OREX : 3.37 (-6.65%)
Orexigen Inks Commercialization Deal for Contrave, Stock Up

Orexigen Therapeutics, Inc.'s (OREX) announced that it has entered into a commercialization and distributorship agreement with Italian pharmaceutical company, Bruno Farmaceutici, for its obesity drug,...

OREX : 3.37 (-6.65%)
NVO : 38.68 (-0.26%)
VVUS : 1.01 (-1.94%)
VRX : 9.25 (-1.39%)
Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Bruno Farmaceutici S.p.A. for Mysimba® (naltrexone HCl / bupropion HCl prolonged release) in Italy

Orexigen Therapeutics, Inc. (NASDAQ: OREX) today announced that its wholly owned subsidiary, Orexigen Therapeutics Ireland Ltd., and Bruno Farmaceutici S.p.A. (Bruno) have executed a distributorship agreement...

OREX : 3.37 (-6.65%)
How These Drug Makers Stocks are Faring? -- Orexigen Therapeutics, United Therapeutics, DURECT, and SciClone Pharma

For today, Stock-Callers.com draws attention to select Drug Manufacturers stocks, namely: Orexigen Therapeutics Inc. (NASDAQ: OREX), United Therapeutics Corp. (NASDAQ: UTHR), DURECT Corp. (NASDAQ: DRRX),...

OREX : 3.37 (-6.65%)
DRRX : 0.88 (unch)
SCLN : 9.65 (-3.02%)
UTHR : 125.70 (+4.32%)
Orexigen Therapeutics to Provide Business Update and Discuss Fourth Quarter and Year End 2016 Financial Results on March 28, 2017

Orexigen Therapeutics, Inc. (NASDAQ: OREX) will announce corporate and financial results for the fourth quarter and full year 2016 on Tuesday, March 28th before the market opens. Following the announcement,...

OREX : 3.37 (-6.65%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

OREXIGEN THERAPEUTICS, INC. is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of central nervous system disorders, including obesity. The Company's lead combination product candidates targeted for obesity are Contrave, which is in Phase III...

See More

Support & Resistance

2nd Resistance Point 3.90
1st Resistance Point 3.63
Last Price 3.37
1st Support Level 3.09
2nd Support Level 2.82

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.